MET and cancer: Interestingly, the targetable genes (by administering e.g. cobimetinib, trastuzumab, and ponatinib, respectively, against) MET, HER2, and FGFR2 also displayed the highest difference with a fold change of the mean expressions over 2 when comparing gastric normal and cancer samples.